Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Ionomr Innovations Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct examiners, though they are both located within 1 distinct art unit. This structure indicates that while the company is interacting with multiple individuals, its technical focus remains consolidated within a single specialized group at the patent office.
The busiest examiner, ZHANG, MICHAEL N, is currently handling 1 busiest examiner pending action. Since there are 2 pending office actions in total, the workload is distributed across the 2 distinct examiners. This arrangement requires the company to adapt to different examiner preferences while operating under the unified guidelines of 1 distinct art unit in the Biotechnology & Pharmaceuticals sector.
Practitioners should note that the assigned personnel provide a level of variety in the prosecution process, even though the same technical group keeps the context consistent. This balance allows for some diversification of risk across different personnel without the need to navigate the varying standards of multiple art units. The focus on Biotechnology & Pharmaceuticals suggests a high level of technical specificity in the current applications handled by ZHANG, MICHAEL N.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHANG, MICHAEL N | 1 | 54.2% | +23.3% |
| WHEELER, THURMAN MICHAEL | 1 | 45.8% | +23.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18551105 | ANTIVIRAL AND ANTIMICROBIAL COATINGS AND METHODS THEREOF | WHEELER, THURMAN MICHAEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18933694 | CROSS-LINKED ARYLIMIDAZOLIUM POLYMERS AND USES THEREOF | ZHANG, MICHAEL N | — |
| 18551105 | ANTIVIRAL AND ANTIMICROBIAL COATINGS AND METHODS THEREOF | WHEELER, THURMAN MICHAEL | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18933694 | CROSS-LINKED ARYLIMIDAZOLIUM POLYMERS AND USES THEREOF | ZHANG, MICHAEL N | — | §112 | Non-Final OA | — | Pending | Oct 31, 2024 |
| 18551105 | ANTIVIRAL AND ANTIMICROBIAL COATINGS AND METHODS THEREOF | WHEELER, THURMAN MICHAEL | 1619 | §103§112 | Non-Final OA | — | Pending | Sep 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial